READOUT // 04 — DOSAGE CONTEXT
MOTS-c peptide dosage, read as research context only
What animal studies administered — dose, route, frequency — and the hard fact that no validated human pharmacokinetics or dosing exists.
Start here
This page describes the MOTS-c peptide dosage figures that appear in published research — and only those. Every number below was given to mice or used in cell culture by scientists running an experiment. None of it is a human dose, because no human dosing schedule for MOTS-c has ever been validated. There is also no measured human half-life. So read what follows as a record of how studies were designed, not as instructions: the figures cannot be scaled to people, and this site provides no human-use guidance.
MOTS-c Dosage in the Research Literature
Across the rodent literature, MOTS-c was administered in a band from roughly 0.5 to 15 mg/kg/day, with the specific figure tied to the study design. In the founding 2015 metabolic work, chronic dosing ran at 0.5 mg/kg/day intraperitoneally over about eight weeks, with a higher acute regimen of 5 mg/kg/day for seven days [1]. The 2021 exercise-capacity study used 15 mg/kg/day, or 15 mg/kg three times weekly, by intraperitoneal injection in mice aged 2, 12, and 22 months [2]. The 2016 bone study used 5 mg/kg/day intraperitoneally for 12 weeks in ovariectomized mice [7]. These are the routes studied in MOTS-c research and the doses on record — research design figures, each cited, none transferable to humans [4].
Two features of these figures deserve emphasis. First, they are weight-normalized (milligrams per kilogram of body weight) in mice, and species differences in metabolism, surface area, and clearance mean a mouse mg/kg figure does not convert to a human dose by simple arithmetic [4]. Second, the dose was matched to the question: the metabolic studies used lower chronic doses to model long-term homeostasis [1], while the exercise study used a higher dose to probe acute and repeated performance effects [2]. A study's dose reflects its experimental design, not an optimized or recommended amount for any organism — least of all a human, for whom no dose has been established.
Routes Studied: Intraperitoneal and Subcutaneous Administration
Intraperitoneal (IP) injection — delivery into the abdominal cavity — is the dominant route in MOTS-c rodent studies, used in the metabolic, exercise, bone, and membrane-repair work [1][2][7][14]. Subcutaneous injection has been used in research contexts, and in-vitro studies apply the peptide directly to cell culture [3]. Because native MOTS-c is a small unmodified peptide and is expected to be short-lived, researchers have also engineered cell-penetrating analogues to improve delivery in some experiments. None of these routes corresponds to a validated human administration method, and no human injection guidance is provided here.
MOTS-c injection: how the routes were used in studies
MOTS-c injection in the literature means intraperitoneal injection in rodents — the route behind nearly all in-vivo findings [1][2] — with subcutaneous administration used in some research settings. There is no human injection protocol in the published record, and none is offered on this page [4].
MOTS-c Half-Life: What the Research Does and Does Not Show
No validated human pharmacokinetic half-life for MOTS-c has been published. As a small unmodified peptide, native MOTS-c is expected to be short-lived in circulation, and published in-vivo work relies on repeated daily or thrice-weekly dosing rather than a measured human t½ [2]. That dosing pattern — once-daily or three-times-weekly in the rodent studies [1][2][7] — is itself the clearest signal that the peptide does not persist long. Small unmodified peptides are generally cleared quickly by enzymatic degradation and renal filtration, which is consistent with the repeated-dosing designs the literature uses.
Engineered cell-penetrating analogues have been developed to improve delivery in some experiments, but those are modified constructs and do not establish a half-life for the native peptide [4]. The practical takeaway is a boundary, not a number: anyone citing a specific human half-life figure for MOTS-c is citing something the published literature does not contain [4]. Where the data are absent, this readout marks the gap rather than estimating across it.
Formulation and Stability Notes
In research, MOTS-c is supplied as a lyophilized (freeze-dried) powder, with reconstitution and storage conditions that are vendor- and study-specific [4]. There is no standardized human formulation, and product purity, identity, and sterility are not regulated as pharmaceuticals — they vary by supplier. The human evidence base, by contrast, is observational rather than dose-driven: circulating MOTS-c is decreased in obese children, associated with insulin resistance, altered by exercise, and independently associated with mortality and cardiovascular risk in hemodialysis patients [10]. Every dose figure on this page is from animal research and must not be read as human dosing guidance.
How often do you inject MOTS-c?
There is no human dosing schedule [4]. Published in-vivo work used daily or thrice-weekly intraperitoneal injection in rodents (for example, 15 mg/kg/day or 15 mg/kg 3×/week) [2], which cannot be extrapolated to humans.
Where is best to inject MOTS-c?
Research used intraperitoneal injection in rodents and subcutaneous routes in research contexts [1][2]. No human injection-site guidance exists, and none is provided here.
Can I inject MOTS-c every day?
Daily intraperitoneal dosing was used in some rodent studies [1][2], but no human dosing schedule has been validated and none should be inferred from animal protocols [4].
How long should you take MOTS-c?
No human treatment duration exists [4]. Rodent studies ran from days to several weeks — roughly 8 weeks for the chronic metabolic work [1] and 12 weeks in the bone study [7] — which is research design, not human guidance.